U.S. FDA may not review new COVID-19 vaccine EUA requests during pandemic – Reuters

A woman holds a small bottle labelled with a “Coronavirus COVID-19 Vaccine” sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo

The U.S. Food and Drug Administration said on Tuesday it may decline to review and process new emergency use authorization (EUA) requests for COVID-19 vaccines for the rest of the pandemic, if a company has not already begun discussions.

So far, vaccines from Pfizer Inc (PFE.N), Moderna Inc (MRNA.O) and Johnson & Johnson (JNJ.N) have been authorized for emergency use in the United States. (https://bit.ly/3fOpP2S)

Novavax Inc (NVAX.O) has had discussions with regulators and said it does not expect to seek regulatory authorization for its COVID-19 shot in the United States, Britain and Europe until the third quarter of 2021. read more

Canadian drug developer Medicago said it was in discussions with the FDA for an EUA for its plant-based COVID-19 vaccine candidate, which is enhanced by a GlaxoSmithKline (GSK.L) treatment.

AstraZeneca (AZN.L) also has discussed plans for its COVID-19 vaccine with U.S. officials. However, the Wall Street Journal earlier this month reported that it was considering skipping U.S. emergency-use authorization and instead pursue the more time-intensive application for a full-fledged license to sell the shot. read more

AstraZeneca and Novavax did not immediately respond to requests for comment.

Our Standards: The Thomson Reuters Trust Principles.

Sorgente articolo:
U.S. FDA may not review new COVID-19 vaccine EUA requests during pandemic – Reuters

User ID Campaign ID Link
d9a95efa0a2845057476957a427b0499 l-99999983 Fiasconaro
d9a95efa0a2845057476957a427b0499 l-99999984 Cloud Real Time
d9a95efa0a2845057476957a427b0499 l-99999996 Webinar Software
d9a95efa0a2845057476957a427b0499 l-99999979 Ugo Fiasconaro